Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco
Phio Pharmaceuticals (Nasdaq: PHIO) announced that its Principal Executive Officer, Robert Bitterman, will present at the Entrepreneurial Showcase during the Dermatology Summit in San Francisco on January 8, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phio Pharmaceuticals (Nasdaq: PHIO) announced that its Principal Executive Officer, Robert Bitterman, will present at the Entrepreneurial Showcase during the Dermatology Summit in San Francisco on January 8, 2023. He will highlight the company's proprietary INTASYL™ RNAi platform, which aims to enhance the effectiveness of immune cells against tumor cells. INTASYL is distinguished as the only self-delivering RNAi technology tailored for immuno-oncology therapeutics. Bitterman has a history of leading dermatological product development and commercialization.
Positive
- Robert Bitterman to present innovations in dermatological cancers, representing Phio Pharmaceuticals.
- INTASYL™ RNAi platform showcased as a unique self-delivering technology in immuno-oncology.
Negative
- None.
Details
News Market Reaction – PHIO
The recorded move for PHIO in the trading session of this news was +2.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARLBOROUGH, Mass., Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its Principal Executive Officer and Executive Chairman, Robert Bitterman, will be a featured speaker at the Entrepreneurial Showcase at the Dermatology Summit in San Francisco on January 8th. The Dermatology Summit is taking place at the Hyatt Regency, alongside the annual JPMorgan Healthcare Conference.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Mr. Bitterman will discuss innovations in dermatological cancers, highlighting Phio's proprietary INASTYL™ platform. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics.
Mr. Bitterman was recently appointed to his leadership role at Phio. He previously led Cutanea and Dermik in the development and commercialization of small molecule dermatological products.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/phio-showcases-innovations-in-dermatology-cancers-at-2023-dermatology-summit-in-san-francisco-301715760.html
SOURCE Phio Pharmaceuticals Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.